Trials / Completed
CompletedNCT03140930
The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Rationale: The appearance of tastants in the small intestine can result in the activation of a negative feedback mechanism from different parts of the intestine to the stomach, the small intestine and to the central nervous system. These processes inhibit food processing, appetite sensations and food intake, and furthermore they increase feelings of satiety and satiation. The effects of intraduodenal and/or intraileal infusion of a combination of tastants (sweet (rebaudioside A), bitter (quinine) en umami (monosodium glutamate(MSG))) and placebo on ad libitum food intake, satiation and gastrointestinal symptoms will be investigated. Objective: To investigate the effect of intraduodenal, intraileal and combined infusion of a combination of tastants versus infusion of placebo on food intake. Secondary objectives: 1. To compare the effect of intraduodenal versus intraileal versus combined intraduodenal and intraileal delivery of a combination of tastants on satiation. 2. To assess the effect of intraduodenal and/or intraileal delivery of a combination of tastants on gastrointestinal symptoms/complaints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Tastants duodenal | Duodenal infusion of combination of tastants (sweet, bitter and umami) |
| DIETARY_SUPPLEMENT | Tastants ileal | Ileal infusion of combination of tastants (sweet, bitter and umami) |
| DIETARY_SUPPLEMENT | Placebo duodenal | Duodenal infusion of placebo (tap water) |
| DIETARY_SUPPLEMENT | Placebo ileal | Ileal infusion of placebo (tap water) |
Timeline
- Start date
- 2017-05-12
- Primary completion
- 2018-05-31
- Completion
- 2018-05-31
- First posted
- 2017-05-04
- Last updated
- 2019-11-15
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03140930. Inclusion in this directory is not an endorsement.